Virtu Financial LLC Acquires Shares of 15,263 Metagenomi, Inc. (NASDAQ:MGX)

Virtu Financial LLC acquired a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,263 shares of the company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after buying an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Metagenomi by 209.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares during the period. Novo Holdings A S boosted its holdings in shares of Metagenomi by 3.5% during the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after purchasing an additional 60,825 shares during the period. Verition Fund Management LLC bought a new stake in shares of Metagenomi in the third quarter worth about $82,000. Finally, Green Alpha Advisors LLC purchased a new position in Metagenomi during the 3rd quarter valued at about $69,000.

Metagenomi Stock Performance

MGX opened at $4.05 on Friday. Metagenomi, Inc. has a 52 week low of $1.61 and a 52 week high of $12.74. The business has a 50 day moving average of $2.31 and a 200-day moving average of $3.18.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MGX shares. Chardan Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright lifted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.67.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.